Search for: "Forest Laboratories, Inc."
Results 1 - 20 of 53
Sorted by Relevance | Sort by Date
7 Apr, 2008 9:53 pm
By Kevin E. Noonan -- The echoes of the Supreme Court's recent spate of reversing the Federal Circuit continue to reverberate, and perhaps nowhere so loudly as in the Federal Circuit's
developing declaratory judgment jurisprudence. Or perhaps it would be more accurate to say in the total collapse of that...
5 Sep, 2007 8:38 pm
By Kevin E. Noonan -- The Federal Circuit today affirmed a District Court finding that ANDA filer Ivax Pharmaceuticals and co-Defendant Cipla had not shown by clear and convincing
evidence that Forest Laboratories' patent-in-suit for Lexapro® was invalid. In doing so, the CAFC answered (for now) the question of
whether...
12 Nov, 2008 4:09 pm
On Monday, November 10, 2008, Forest Laboratories, Inc. filed a quarterly report with the Securities and Exchange Commission,
revealing that it had agreed in principle to a settlement amounting to $65 million in In re: Forest Laboratories, Inc. Securities
Litigation, 05-cv-02827 (S.D. NY).
25 Aug, 2008 4:10 am
... declaratory judgment jurisdiction jurisprudence ever since the Supreme Court's Medimmune, Inc. v. Genentech, Inc. decision. These cases have included SanDisk Corp. v.
... Pharmaceuticals Corp., Benitec Australia, Ltd. v. Nucleonics, Inc., Caraco Pharmaceutical Laboratories, Ltd. v. Forest
Laboratories, Inc., and just last week, Prasco LLC v ... trend continues, albeit in a nonprecedential opinion, in Merck & Co. v. Apotex Inc. In a per curiam
decision from a panel made up of CAFC Judges Mayer and ...
11 Sep, 2008 4:55 am
... have been directed to the proper jurisdictional scope of declaratory judgment actions filed in ANDA cases, where a generic drug company has filed its ANDA on a drug having at least
one patent listed by the innovator in the FDA Orange Book. These cases include Caraco Pharmaceutical Laboratories, Ltd. v. Forest
Laboratories, Inc. and Merck & Co. v. Apotex,...
7 Apr, 2008 10:55 am
... as in matters relating to pharmaceutical products. Specifically, the court held in Caraco Pharmaceutical Laboratories, Inc, Ltd. v. Forest Laboratories, Inc. (April 1, 2008) that the district court had erred in declining to exercise jurisdiction ... approval to market its
generic product. In an attempt to prevent Caraco from raising invalidity via a declaratory judgment action, Forest gave Caraco a covenant not
to sue on the '941 patent. Based on that covenant, the district court granted Forest's ...
17 Jan, 2008 10:00 pm
... infringement case so Novartis and Apotex can attempt to reach a settlement: (IP Law360), Namenda (Memantine) - Forest Laboratories
Inc. file patent infringement lawsuits against Teva, Barr and others seeking to sell generic ... copyright infringement action against LensWorld for keyword advertising and
mimicking their FAQs: (Trademark Blog) Abbott Laboratories - Abbott appeals a multiplicity of issues with varying success in its patent dispute with Innogenetics : (Patently-O),
(Patent Prospector), ...
5 Sep, 2007 11:40 am
... ANDA) to the FDA seeking approval to market generic tablets containing escitalopram oxalate ("EO"), the active ingredient in Lexapro®. Forest Laboratories, Inc., which owns the patent for Lexapro®, sued Ivax under the Hatch-Waxman Act, which provides that the mere filing of an
ANDA is an act of infringement. During discovery, Forest learned that part of Ivax's ANDA submission included information provided by
Mumbai-based Cipla, Ltd., Ivax's alleged EO ...
5 Sep, 2007 11:40 am
... ANDA) to the FDA seeking approval to market generic tablets containing escitalopram oxalate ("EO"), the active ingredient in Lexapro®. Forest Laboratories, Inc., which owns the patent for Lexapro®, sued Ivax under the Hatch-Waxman Act, which provides that the mere filing of an
ANDA is an act of infringement. During discovery, Forest learned that part of Ivax's ANDA submission included information provided by
Mumbai-based Cipla, Ltd., Ivax's alleged EO ...
1 Jun 3:36 am
... MDL because they involved injuries other than suicide. The new suit, Universal Care, Inc., et al. v. Forest Laboratories,
Inc., et al., on the other hand, involves allegations relating to Forest Laboratories Inc.'s ... Merchandising Practices
Act and makes claims for unjust enrichment, fraudulent concealment , and misrepresentation. The plaintiffs in this case claim that Forest
engaged in improper promotional activities, causing third-party payors to reimburse patients and health care institutions ...
13 Feb, 2008 6:19 pm
... brand and generic drug makers (source: Justia). #7: Forest Laboratories, Inc. v. Lupin Pharmaceuticals, Inc., No.
1:2008cv00239, filed January 28, 2008; ... Book-listed U.S. Patent No. 5,061,703. Plaintiff Forest Labs. Holdings, Ltd., is an Irish company
based in Bermuda; plaintiffs Merz Pharma ... because they claim not to be able to determine with certainty which one of Lupin, Inc., or Lupin Ltd. was the actual filer of the
ANDA. This move was in anticipation of a jurisdictional challenge by Lupin ( ...
7 Oct 6:44 am
... construction objections. Such validity arguments are not properly resolved at the claim construction stage." The Court's decision stands as a warning to D. Del. practitioners:
aggressive Markman tactics will not succeed in this district. (See also footnote 5 of the Court's opinion.) Forest Laboratories
Inc. v. Cobalt Laboratories Inc., C.A. No. 08-021-GMS-LPS (D. Del. Sept. 21, 2009) (Sleet, C.J.).
11 Apr, 2008 9:00 am
... (IP Law360), (GenericsWeb), Lexapro (Escitalopram) - CAFC decision in Caraco Pharmaceutical Laboratories, Ltd. v. Forest
Laboratories, Inc. turns law of declaratory judgment on its head: (Patent Docs), ... - US CAFC upholds Ortho-McNeil's Topamax patent in dispute with Mylan
Laboratories and in companion case against Cobalt Pharmaceuticals: (Patent Docs), (IPBiz), (Patent Docs ... but not false advertising claim: Trans USA Products, Inc v
Howard Berger Company, Inc: (43(B)log), Tyco - Common law claims ...
6 Feb 8:19 am
... The filings are below. __________________ Docket: 08-457 Title: International Shipping Agency, Inc., v. Puerto Rico Ports Authority, et al. Issue: Whether a state-created ...
of petitioner) __________________ Docket: 08-624 Title: Forest Laboratories, Inc., et al., v. Caraco Pharmaceutical
Laboratories, Ltd. Issue: Whether a generic drug company has ... Docket: 08-754 Title: Singleton, et al., v. Volkswagen of America, Inc., et al. Issue: Whether and under
what circumstances a court of appeals may issue ...
3 Mar 12:06 pm
... Celexa and Lexapro for unapproved pediatric use and for paying doctors to prescribe the drug through illegal kickbacks. Forest
Laboratories Inc. is charged with influencing doctors with cash payments disguised as grants. The company was prohibited from promoting the drugs for pediatric use ...
dangerous in a double-blind, placebo-controlled pediatric trial. Click here to read the full article, "United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act."
28 Aug, 2008 4:24 am
... class action In re Forest Laboratories, Inc. Securities Litigation, 1:05-cv-02827 (S.D.N.Y.), has been set for trial on
November ... Court of New York in March 2005, the action is being prosecuted by class representatives who claim that Forest violated federal
securities laws in marketing and promoting its SSRI antidepressants, Celexa ... notice stipulation, the court set the trial date for November 3, 2008. Notably, in Forest's August 8, 2008 filing with the federal Securities and Exchange Commission ...
29 Jul, 2008 3:01 pm
... 4:06-md-01736 (RWS), a Multidistrict Litigation with approximately 42 cases alleging suicidal injuries caused by either Celexa or Lexapro, the defendants, Forest Laboratories, Inc. and Forest Pharmaceuticals, Inc. moved to dismiss 22 of the cases on
conflict preemption grounds. The cases in question all involved plaintiffs or decedents who were over the age of 24 at the time of their suicidal event or their suicide.
21 Oct 9:54 pm
... in the U.S. District Court for the Southern District of New York has awarded Infosint $15 million as a reasonable royalty in Infosint's patent dispute with Lundbeck A/S and
Forest Laboratories, Inc. over the patent covering Lexapro®. The patent-in-suit, U.S. Patent No. 6,458, ... antidepressant
marketed under the trade names Celexa® and Lexapro®. In the suit, originally filed in April 2006, Infosint accused both Lundbeck and Forest
Labs of infringing the '973 patent. In response,...
5 Sep, 2007 3:50 pm
... the time to give them the attention they doubtless deserve and therefore offer a mere summary (with links!): Zila, Inc. v. Tinnell, No. 05-15031 (9th Cir. Sept. 5, 2007) --
Can a U.S. patent ... the U.S. patent? No, but he can get them for a Canadian patent. Forest Laboratories, Inc. v. Ivax
Pharmaceuticals, Inc., No. 07-1059 (Fed. Cir. Sept. 5, 2007) -- Validity of a "reissue" patent on escitalopram oxalate as against allegations of anticipation, obviousness, and
improper broadening. Mitutoyo Corp. ...
2 May, 2007 9:17 am
... the year the agency warned the public about the risks of the drugs in children. The proposed label changes would apply to all antidepressants, including Lexapro (Forest Laboratories Inc.), Paxil (GlaxoSmithKline PLC), Prozac (Eli Lilly and Co.) and Zoloft (Pfizer Inc.). Some of the drugs are
available in generic form as well. Messages left with the companies were not immediately returned.
Search on: Blawgs.FM | BlawgSearch Google Co-op |
Blawg.com | Bloglines | Feedster | Google Blog Search |
Technorati | Google | MSN | Yahoo!